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The SARS-CoV-2 Delta variant, known as B.1.617.2 and first identified in India, is becoming
a dominant strain in many countries due to its extreme infectiousness. Assessing and
quantifying the transmissibility and competitive advantage of the Delta variant is of major
significance for countries around the world so that appropriate measures to mitigate and
even eliminate the epidemic can be introduced. Aiming at such problems, we proposed a
method to model the invasion process of a novel strain and estimate the competitive
advantage of the invading strain over the local strain. We applied this method to study the
invasion and spread of the Delta variant into England. We have estimated the basic
reproduction number of the Delta variant as being 49% higher than that of the Alpha
variant (CI: 45e52%), assuming a mean generation interval of 5 days with a standard
deviation of 3 days. In the period 11 April to 17 May 2021, the effective reproduction
number of the Delta variant was 65% higher than that of the Alpha variant in England (CI:
61e70%). Our results show that the Delta variant has a significantly higher transmission
capacity than other strains, which explains the rebound of the epidemic in many countries,
even in those with relatively high vaccination coverages.
© 2021 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications
Co. Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The SARS-CoV-2 Delta variant, known as B.1.617.2 and first identified in India, is a variant of the SARS-CoV-2 lineage B.1.617.
It was characterized as a VOC (Variant of Concern) on 11 May 2021 and later termed the Delta variant by the World Health
Organization (WHO) under a new naming system introduced on 31 May 2021 (WHO, 2021a). The Delta variant has been
spreading quickly and had appeared in more than 60 countries by June 2021 (WHO, 2021b). On 18 June 2021 the WHO chief
scientist said that the Delta variant is “well on its way to becoming the dominant variant globally” (New Scientist, 2021). There
is evidence showing that this variant that has taken over from the Alpha variant (lineage B.1.1.7) is clearly significantly morend Statistics Xi'an Jiaotong University, Xi'an, 710049, PR China.
.
unications Co., Ltd.
by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC
ses/by-nc-nd/4.0/).
F. Xia, X. Yang, R.A. Cheke et al. Infectious Disease Modelling 6 (2021) 988e996infectious (WHO, 2021b). Therefore, assessing and quantifying the transmissibility of the Delta variant is of great significance
for countries around the world so that they can introduce appropriate measures to mitigate and even eliminate the epidemic.
The most widely used epidemiological measurement of the transmissibility in a given population is the basic reproduction
number, R0, which is defined as the average number of secondary cases generated by a single primary case in a fully sus-
ceptible population. This indicator reflects the intensity of non-pharmaceutical interventions needed to control the epidemic
and the proportion of the immune population needed to form herd immunity, hence it is of great significance for under-
standing and controlling the epidemic. The estimation of R0 should be based on the data during the early stage of the outbreak
when there were no prevention/control measures or immunizations. When the Delta variant emerged, however, a proportion
of the population had already developed antibodies due to infection or mass vaccination and the contact rate has not
recovered to the normal level, thus the time series data for Delta cases was difficult to use directly for estimating its basic
reproduction number R0.
In view of this situation, we proposed a statistical model based on the renewal equation, which describes the process of a
variant invading and replacing the local strain, to estimate the competitive advantage of the invading variant over the local
strain and consequently obtain the basic reproduction number R0 for the invading variant indirectly.We then applied this idea
to model the process of the Delta variant invading England and estimate the transmissibility of the Delta variant.2. Methods
As a complement to the basic reproduction number R0, the effective reproduction number, Rt, which is defined as the
actual average number of secondary cases per primary case at time t, can be used to access time-dependent variations in the
transmission potential when infection is spreading in a population (Wallinga & Teunis, 2004). Both of these two types of
reproduction numbers were used to characterize the spread of the disease in our analysis.
In this section we denote the local strain and the invading strain by strain a and strain d, respectively. The basic repro-
duction number and the effective reproduction number of strain i are denoted by Ri0 and R
i
t for i ¼ a, d.
Let Lat be the number of new cases with strain a on day t, then we have the following renewal equation which models the
transmission of strain a and the relationship between the reproduction number and the infection incidence (Wallinga &
Lipsitch, 2007):
E½Lat





where fgat gt¼1;2;… represents the discretized probability distribution of the generation interval (i.e. time from the infection of







ts, the sum of cases up to day t  1, weighted by the infectivity function gat , indicates the total
infectiousness of infected individuals on day t. Here t ¼ 1 is the initial time at which the first local case emerged.
Given that during the early stage of the strain invasion most cases with the invading strain are imported cases, we divided
cases with strain d into three classes, namely 1). imported cases, 2). secondary cases of primary imported cases and 3). local




t . Again, let
fgdt gt¼1;2;… be the discretized generation interval distribution of strain d, from the renewal equation we have
E½Kdt







Rdt  ¼ Rdt Xt1
s¼1
ðKds þ LdsÞgdts; (3)
with a 2 (0, 1) indicates the ratio of the transmissibility of imported cases to that of non-imported cases.
In order to parameterize the competitive relationship between strain d and strain a, we introduce a function F as follows:
Rdt ¼ Fðt;Rat Þ; (4)
here F describes how the difference in the spreading ability of the two strains changes over time and reflects the competitive
advantage of strain d over strain a.
To obtain the specific form of F under the scenario of mass vaccination, we consider the following SIR model:989
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
N  ðgi þ diÞIi; i ¼ a; d:
dR
dt
¼ gaIa þ gdId:
(5)In which the population is stratified as susceptible (S), vaccinated (V), infected (I) and recovered (R) compartments.
Subscripts I, II represent vaccination with only a single dose, and with two doses, respectively. Subscripts i ¼ a, d represent
strain i. N is the total population. eiI and e
i
II indicate the efficacy of the first and the second doses of the vaccine to strain i.
Parameters b, g and d are the transmission rate, recovery rate and death rate, respectively.
Following the next generation matrix method (Van den Driessche & Watmough, 2002), we define
Hi ¼ bicðtÞIi½Sþð1 eiIÞVI þð1 eiIIÞVII
.
N (6)
andVi ¼ ðgi þdiÞIi (7)
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; i ¼ a; d: (10)Define the effective population susceptible to strain i as
SieðtÞ ¼ SðtÞ þ ð1 eiIÞVIðtÞ þ ð1 eiIIÞVIIðtÞ; i ¼ a; d: (11)
and let b ¼ Rd0=Ra0, ft ¼ S
d
eðtÞ







,Rat ¼ b,ft,Rat (12)
andFðt;Rat Þ ¼ b,ft,Rat : (13)It can be verified that the above relationship between reproduction numbers of different strains is valid for general SIR-
type or SEIR-type compartmental models.
We estimate the reproduction number for the period t0  t  t1. Set the time window of reproduction numbers to t days,
i.e. for i ¼ a, d and m ¼ 1, 2, …, the effective reproduction number Rit during the period t 2 [t0 þ (m  1)t, t0 þ mt  1] is990















































where P(x) ¼ lxexp(l)/(x!) is the probability mass function of a Poisson distribution with mean l and l(x) ¼ x ln(E[x])  E
[x] ln(x!).M is the maximum integer such that t0 þMt 1 t1. Means of Lat , Kdt and Ldt are given by formulas (1), (2) and (3).



































ðaJds þ Lds þ KdsÞgdjs
:
(15)In the above equations, the index of summation m ranges from 1 to M and the index of summation j ranges from
t0 þ (m  1)t to min(t0 þ mt  1, t1).
3. A case study: application to model the invasion of the delta variant into england
Outside India, the UK has recorded the highest number of Delta cases (PANGOlineages, 2021). The Delta variant was first
introduced into England in March 2021 when the Alpha variant was the dominant local strain, then it began to spread locally
in April and became dominated by the end ofMay (Public Health England, 2021a). Since thewhole process of the Delta variant
replacing the Alpha variant was observed in England and the associated sequencing data on such COVID-19 cases are
available, our study is based on the epidemic data in England. In the following we use notations a and d to indicate the Alpha
variant and the Delta variant, respectively. The initial time t ¼ 1 is set to 1 March 2021.
3.1. Data
We obtained the daily number of laboratory-confirmed COVID-19 cases in England from (The official UK government
website for data and insights on coronavirus (COVID-19), 2021a) (bars in Fig. 1 (A)) and obtained sequencing data on part of
these confirmed cases from (Public Health England, 2021a). Sequencing data include the daily percentage of sequenced
confirmed cases (blue line in Fig. 1 (B)), the weekly proportion of Alpha cases amongst all sequenced cases (dots in Fig. 1 (A))
and daily travel data for confirmed Delta cases (bars in Fig. 1 (B)). All of the above data are presented by specimen date (the
date when the sample was taken from the person being tested). Since sequencing datawere released on 31May 2021, data on
the previous 14 days before this day are still accumulating and the proportions are less likely to accurately reflect prevalence,
so we only used data up to 17 May 2021.
3.2. Estimation of case numbers
The proportion of cases for the Alpha variant inweekly sequenced cases is shown in blue dots in Fig.1 (A), and is fittedwith
a smooth spline function over time, denoted by hat . Then the daily number of new cases, denoted by Ct is multiplied by the
fitting function hat to get the daily number of new Alpha cases, denoted by L
a
t shown in dark blue bars in Fig. 1 (A), then we
have
Lat ¼ Cthat : (16)991
Fig. 1. Data and analysis for epidemics in England: (A). Bars represent the daily number of laboratory-confirmed COVID-19 cases, dots represent the proportion of
Alpha cases in weekly sequenced cases. The line is the curve fitted to the dots and represents the proportion of Alpha cases in daily newly confirmed cases, which
we divided into the daily confirmed Alpha cases (dark bars) and non-Alpha cases (light bars); (B). Data for confirmed Delta cases (bars) and the proportion of
sequenced cases in all cases (blue line); (C). Estimated number of Delta cases among all confirmed cases; (D). Estimated effective reproduction number and fitted
number of confirmed cases of the Alpha variant (blue) and the Delta variant (yellow). Dots and solid lines represent the number of new cases and its fitted value.
Dotted lines in blue and yellow represent estimated effective reproduction numbers. The green dotted line is the blue dotted line multiplied by b ¼ 1.49; (E).
Variation of b when the generation interval varies. The shaded region represents the 95% confidence interval; (F). Estimated value of the basic reproduction
number of the Delta variant. All dates are in the year 2021.
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traveller (Cct ), not travel-associated cases (C
n
t ) and cases of unknown origin (C
u
t ), and the blue curve represents the proportion
of daily confirmed cases that were sequenced, denoted by function pt. It is reasonable to assume that the unknown cases may
only contain two groups, that is those resulting from contacts with a traveller or those that are not travel-associated, due to
clear information on travelling histories. Suppose that the ratios of confirmed cases that are from contacts with a traveller or
not travel-associated are the same as those for the unknown cases, from which we can divide the unknown cases into the
group of contacts with a traveller and the group of not travel-associated. As shown in Fig.1 (C), by using the function pt, we can
further estimate the number of Delta cases among confirmed cases that are travellers (denoted by Jdt ), derived from contact
with a traveller (denoted by Kdt ) or not travel-associated (denoted by L
d
t ), that is,992
















Lt ¼ Ct þ Ct ,Cct þ Cnt
pt : (19)3.3. Vaccinations in England and the resistance of the delta variant to vaccines
According to section 2, for the effective reproduction numbers of the Delta and Alpha variants we have
Rdt ¼ b,ft,Rat ; (20)
where b is the ratio of the basic reproduction number for the Delta variant to that for the Alpha variant and ft ¼ SdeðtÞ= Sae ðtÞ.
Here Sie is calculated as
SieðtÞ ¼
0




Aþ ð1 eiIÞVIðtÞ þ ð1 eiIIÞVIIðtÞ (21)
for i ¼ a, d andPj  tCj refers to the cumulative number of cases from the beginning of the epidemic up to time t in England.
We obtained the data on vaccinations in England from (The official UK government website for data and insights on
coronavirus (COVID-19), 2021b). As shown in Fig. 2, the light blue and dark blue lines are the number of peoplewho have been
vaccinated with the first, and with the second doses, respectively. The difference between them (the light shaded region)
equals VI(t) and the dark shaded region equals VII(t). The population of England is N ¼ 56, 287, 000 (Office for National
Statistics, 2021). According to the vaccine effectiveness analyses undertaken by (Public Health England, 2021c), we take eaI ¼
50%, eaII ¼ 88%, edI ¼ 33%, edII ¼ 81%. Then ft ¼ SdeðtÞ=Sae ðtÞ is calculated according to expression (21) and is shown in Fig. 2 (the
yellow line), fromwhich we can see that the increase in the effective reproduction number of the Delta variant compared to
that of the Alpha variant due to the resistance of the Delta variant to the vaccine.
3.4. The effective reproduction number and estimation of the competitive advantage of the delta variant
On the basis of the model in section 2 we estimate the effective reproduction number of the Alpha variant, and the
transmission advantage level of the Delta variant compared to that of the Alpha variant. The starting time for the estimation is
chosen asFig. 2. Number of people who have received 1st (light blue line) and 2nd (dark blue line) dose vaccinations, and the ratio of the effective population susceptible to
the Delta variant to that of the Alpha variant (yellow dotted line). Dates are in the year 2021.
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t
fLdt 10g; (22)
which is the day when the daily number of confirmed local delta cases was more than 10 for the first time, which was on 11
April 2021. Then, according to the statement in section 3.1, we can select t1 as 17 May. The value of ft is given in section 3.3.
Recent findings suggest no significant changes in the generation intervals (GI) for SARS-CoV-2 cases infected with the Delta
variant (Pung et al., 2021), hence we assume the Delta and Alpha variants have the same GI, which is set to a gamma dis-
tribution with a mean of 5 days and standard deviation (std) of 3 days (Nishiura et al., 2020). We set the time window t of
reproduction numbers to be 7 days in likelihood model (14). Then we have 8 parameters in the model, including a, b and
fRam;7g6m¼1. Here R
a
m;7 indicates the effective reproduction number of the Alpha variant over the time interval t0 þ
7(m  1)  t  t0 þ 7m  1. The estimated values for these parameters are listed in Table 1. Data fitting results and the
estimated effective reproduction numbers for the two strains are shown in Fig. 1 (D). The ratio of the basic reproduction
number R0 for the Delta variant to that for the Alpha variant was estimated as b ¼ 1.486 (95% CI: 1.449e1.522).
As illustrated in (Cori et al., 2013), small values of the time window t lead to more rapid detection of changes in trans-
mission but also more statistical noise; large values lead to more smoothing, and reductions in statistical noise. Note that the
number of virus tests conducted in England has a periodicity of one week, which results in the same periodic fluctuation of
the number of confirmed cases. In order to reduce the impact of this system error on our estimations of Rt, in the above
estimation we take the time window t ¼ 7 days which is equal to the period of confirmation time series. To examine the
sensitivity of themain results to the parameter, we let t vary from 1 to 14 days, the estimated value of the parameter b is in the
range of 1.48e1.54, therefore the main conclusion of this paper is not greatly influenced by the choice of t.
Note that GI is not only related to the viral dynamics at the individual level, but it is also affected by isolation and detection
measures. A study in mainland China showed that from early January 2020, the estimated GI for COVID-19 decreased from
more than 7 days to around 3 days in about a month (Ali et al., 2020). This indicates that GI varies with the intensity of
prevention and control measures during the epidemic. To examine variation of the estimated value of parameter bwith GI, we
carried out sensitivity analysis by changing the mean of GI. Our sensitivity analysis indicates that b increases with respect to
GI, shown in Fig. 1 (E), and the range of b is 1.19e1.92 with increasing GI from 3 to 7 days.
Apart from the increase in the basic reproduction number reflected by the parameter b, the competitive advantage of the
Delta variant also involves a reduction in vaccine efficacy against infection for the Delta variant compared to that of the Alpha
variant (Public Health England, 2021b), which is reflected by the parameter ft. We illustrate these two parts of the competitive
advantage of the Delta variant in Fig. 1 (D), in which the green dotted line is bRat and the yellow dotted line is R
d
t ¼ bftRat .
During the period (t0, t1), Rdt is 64.7e65.6% higher than R
a
t (range of 95% CI: 60.7e69.7%), without the reduction in vaccine
efficacy against the Delta variant, this number would reduce to 48.6% (95% CI: 44.9e52.2%).3.5. The basic reproduction number for the delta variant
Note that the estimation of the basic reproduction number R0 should be based on the data at the beginning of the outbreak
when there were no prevention/control measures or immunizations, and then the number of infected people is in the
exponential growth stage. When the Alpha and Delta variants appeared in the UK, the contact rate had not yet returned to the
original level due to gradually lifting of closure measures, and a considerable proportion of the population had already ac-
quired a certain degree of immunity. This consequently leads to direct estimations of the basic reproduction numbers for theTable 1
Estimates (95% confidence intervals) of parameters for different means of the generation interval.
E[GI][1] 3 4 5 (baseline) 6 7
b 1.19 (1.16,1.22) 1.32 (1.29,1.35) 1.49 (1.45,1.52) 1.68 (1.64,1.73) 1.92 (1.87,1.96)
a 0.35 (0.32,0.38) 0.33 (0.30,0.36) 0.30 (0.27,0.33) 0.28 (0.25,0.30) 0.25 (0.23,0.28)
Ram;t[2]
m ¼ 1 0.87 (0.35,1.44) 0.85 (0.30,1.44) 0.82 (0.24,1.45) 0.80 (0.19,1.46) 0.78 (0.14,1.47)
m ¼ 2 0.95 (0.70,1.22) 0.95 (0.69,1.21) 0.94 (0.68,1.21) 0.93 (0.66,1.20) 0.91 (0.64,1.20)
m ¼ 3 0.93 (0.78,1.09) 0.91 (0.76,1.07) 0.89 (0.75,1.04) 0.87 (0.73,1.02) 0.85 (0.72,0.99)
m ¼ 4 0.95 (0.88,1.03) 0.94 (0.87,1.01) 0.92 (0.85,1.00) 0.90 (0.83,0.98) 0.88 (0.81,0.96)
m ¼ 5 0.90 (0.85,0.94) 0.86 (0.82,0.91) 0.83 (0.79,0.87) 0.81 (0.77,0.85) 0.79 (0.75,0.83)
m ¼ 6 1.10 (0.98,1.23) 1.00 (0.90,1.12) 0.92 (0.82,1.02) 0.84 (0.76,0.93) 0.79 (0.71,0.87)
Rdm;t[3]
m ¼ 1 1.15 (0.46,1.90) 1.24 (0.44,2.11) 1.35 (0.40,2.39) 1.49 (0.36,2.73) 1.66 (0.31,3.12)
m ¼ 2 1.26 (0.93,1.61) 1.39 (1.02,1.78) 1.55 (1.12,1.99) 1.73 (1.24,2.25) 1.94 (1.36,2.55)
m ¼ 3 1.23 (1.02,1.44) 1.33 (1.11,1.57) 1.47 (1.23,1.72) 1.63 (1.36,1.90) 1.81 (1.52,2.11)
m ¼ 4 1.25 (1.16,1.35) 1.37 (1.27,1.49) 1.52 (1.40,1.65) 1.69 (1.55,1.83) 1.88 (1.72,2.04)
m ¼ 5 1.18 (1.12,0.24) 1.26 (1.20,1.33) 1.37 (1.31,1.44) 1.51 (1.44,1.59) 1.68 (1.60,1.76)
m ¼ 6 1.45 (1.29,1.62) 1.47 (1.31,1.64) 1.51 (1.35,1.68) 1.58 (1.41,1.75) 1.67 (1.50,1.85)
[1] Themean of the generation interval (days). [2] The effective reproduction numbers of the Alpha variant with the timewindow t¼ 7 days. [3] The effective
reproduction numbers of the Delta variant with the time window t ¼ 7 days.
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duction number of the Delta variant through the basic reproduction number of the original strain and the force of trans-
mission of the Alpha and Delta variants relative to that of the original strain.
Note that it is difficult to accurately estimate the basic reproduction number of SARS-CoV-2, which may be influenced by
the chosen methods, the available data, various populations/regions etc. For estimation of the basic reproduction number of
the original SARS-CoV-2 (denoted by Ro0), the estimated mean value is between 2 and 3 for mainland China (Ahammed et al.,
2021; Li et al., 2020; Riou& Althaus, 2020;Wu et al., 2020), and between 3 and 4 for European countries (Flaxman et al., 2020;
Gatto et al., 2020; Roques et al., 2020; Yuan et al., 2020). Here we chose Ro0 ¼ 2:5, Ro0 ¼ 3:5, and Ra0=Ro0 being in the interval of
[1.4, 1.9] (Davies et al., 2021) as the basis for estimating the basic reproduction number of the Delta variant.





with b ¼ 1.49 (1.45e1.52). Results are shown in Fig. 1 (F). In particular, when the basic reproduction number Ro0 ¼ 2:5, the
estimated value Rd0 is 5.20e7.06 (range of 95% CI: 5.07e7.23), when R
o
0 ¼ 3:5, the estimated value Rd0 is 7.28e9.88 (range of
95% CI: 7.10e10.12).
4. Conclusion and discussion
In this study, we proposed amodel that describes the process of a variant invading and replacing the local strain, which can
be used to estimate the competitive advantage of the variant over the local strain. This model can be applicable for the
situation with mass vaccination rollout and different vaccine efficacies for the invading and the local strains. When the
vaccine efficacies against the two strains are the same, we can omit the consideration of vaccination and simplify formula (13)
to
Fðt;Rat Þ ¼ b,Rat : (24)Our method can also be used to analyze the competitive advantage of a newly-emerging mutant strain over the original
local dominant strain. Assuming that the strain d is a newly-emergingmutant strain, we only need to replace formulas (2) and
(3) in section 2 with
E½Ldt




ts: (25)The proposed model in this study is simple and technical, and the parameter estimation is not computationally costly, so
the approach is easy to be applied for estimations of and comparisons between the transmission ability of different strains.
As an application, we used case data in England to examine the competitive advantage of the Delta variant of SARS-CoV-2
(lineage B.1.617.2), which is spreading rapidly across the world, compared to that of the Alpha variant (lineage B.1.1.7). We
found that the basic reproduction number of the Delta variant is 49% higher than that of the Alpha variant (CI: 45e52%) under
the baseline value (mean GI being 5 days with std 3 days). In the period 11 April to 17 May 2021, the effective reproduction
number of the Delta variant was 65% higher than that of the Alpha variant in England (CI: 61e70%). Moreover, these two
estimates increase with increasing GI. Our results show that competitive advantage of the Delta variant is not only illustrated
by its high basic reproduction number, but also by the low efficacy of vaccinations against it compared with vaccination
efficacies against other strains. The latter has led to the Delta variant replacing other strains more quickly to become the
dominant strain in countries including even those with high vaccination coverages. The findings also show that the Delta
variant has a significantly higher transmission capacity than other strains, which explains the rebound of the epidemic in
many countries, including the United Kingdom, when the proportion of people vaccinated is high and when some prevention
and control measures are still in place.
When many variant strains, including the SARS-CoV-2 Delta variant, were prevalent, a considerable proportion of the
population already had antibodies, and prevention and control measures were still in place, making direct estimations of the
basic reproduction number for variant strains by classical methods very difficult and challenging. Here we also provided a
means of estimating the basic reproduction number indirectly when the classical estimation method is not applicable. In this
study, we infer the basic reproduction number (Rd0) for the Delta variant indirectly by estimating the ratio of the basic
reproduction number R0 for the Delta variant to that for the Alpha variant, parameter b, and using the ratio of R0 for the Alpha
variant to estimates of that for the original strain.
The effective reproduction numbers of Delta and Alpha Variants are estimated and compared based on epidemic data in
England, the results coincide with similar studies, e.g. (Campbell et al., 2021) and (Imperial College London, 2021), in which
the effective reproduction number of the Delta variant is 53% (with mean GI being 5 days) or 100% (with mean GI being 6.7
days) higher than that of the Alpha variant, respectively. Note that such research generally considered the comparison995
F. Xia, X. Yang, R.A. Cheke et al. Infectious Disease Modelling 6 (2021) 988e996between the effective reproduction numbers or the growth rates for various strains for a given time, however these results are
limited by ignorance of the presence of vaccine. Our study further considered the competitive advantage of the Delta variant
against other strains, including the increase in the basic reproductive number (denoted by parameter b) and reduction in
immune efficacy (denoted by function ft). Theoretically our method is not affected by the coverage and efficacy of vaccine.
After adjusting the function ft according to the immune condition of a given population, we can get the competitive and
transmission advantage of the Delta variant in other areas. Therefore our model and results are more universal than other
similar models.
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